A dad who raised an impressive €600k for leukaemia treatment is now switching his focus to China, where a promising new treatment is being developed. CNCT19, an investigational CAR-T cell therapy, has shown significant clinical benefits in treating relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) in adults. The China National Medical Products Administration (NMPA) has accepted Juventas Cell Therapy’s new drug application (NDA) for CNCT19, marking a crucial milestone in making this treatment available to patients in China and potentially worldwide.
Dad’s Leukaemia Fundraising Efforts Shift Focus to China
Share on
Related posts
-
Europe’s Nuclear U-Turn: A Strategic Mistake
The European Union’s decision to reduce its reliance on nuclear energy has been…
-
EU Lawmakers Approve ‘Return Hubs’ for Migrants
The European Union has taken a significant step towards tightening its immigration policy,…
-
Iran’s Attacks on Gulf Energy Installations Send Oil Prices Surging
Iran has launched a series of strikes on energy installations in the Gulf,…
-
Russia Accuses Ukraine of Attacking Gas Tanker in Mediterranean
Russia has blamed Ukraine for a gas tanker explosion that occurred between Malta…
-
China’s National People’s Congress Sets Stage for Economic Future
China’s biggest political meeting, the National People’s Congress (NPC), has kicked off with…
-
Consumer Warnings Issued Against Unlicensed Operators
Regulatory authorities have issued warnings against four unlicensed operators, cautioning consumers about the…
Search
About us
MALTA BULLETIN
Discover Latest News, Hot Topics, Politics and Entertainment News With Malta Bulletin